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right breast (53%) while about 43% had of left breast. Patients with breast cancer 
were mostly married (99%) & patients were belonging to poor socioeconomic 
status. Diagnostic tests performed for most of the cancer patients were 
mammography, biopsy, USG, X-ray & MUGA & bone scan and about 60% of the 
population had undergone mastectomy. CONCLUSIONS: Infiltrating ductal 
carcinoma (96%) was found the most common type of breast cancer in southern 
Punjab. The socioeconomic status of the patients might affect the prevalence of 
breast cancer in patients  
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OBJECTIVES: To evaluate the prevalence and patterns of CAM use among cancer 
patients in Malaysia. In addition, the study focuses on the perceived 
effectiveness of CAM over conventional therapies, information seeking 
behaviour and CAM disclosure to health care providers. METHODS: The study 
was designed as a questionnaire based, cross sectional analysis. A prevalence 
based sample of 393 cancer patients attending the oncology clinics at Penang 
General Hospital was hereby selected for the study. Adult patients (18 years old), 
having diagnosed with cancer (any type), able to read or understand Malay 
(national language of Malaysia) or English language were recruited between 
August to November 2011. RESULTS: Overall, 393 questionnaires were completed 
and included in the analysis, showing that 46.1% of cancer patients had used 
CAM, with most (57.6%) believing that CAM therapies assisted the body’s natural 
forces to heal. CAM usage was significantly associated with gender (P=0.021), 
level of education (P=0.001), employment status (P=0.02) and monthly income 
(P<0.001). Among the frequently used CAM were biologically-based therapies 
including nutritional supplements (used by 75.5% of the participants). Friends 
and family members were the most common source of CAM information (for 
75.5% of the participants). Only 13% reported side effects from using CAM. CAM 
use disclosure to the doctors was 43%; however, doctors had specifically asked 
about CAM use in 33.4% of the cases. The most common reason given for non-
disclosure was ‘it is not important for the doctors to know about CAM use  
(34.2%). CONCLUSIONS: Cancer management and treatment requires compliance 
to effective therapies at early stages. Health care providers should engage cancer 
patients in an open non-judgmental dialogue to ascertain better understanding 
of cancer and its treatment options.  
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OBJECTIVES: Current international guidelines for breast cancer follow-up are not 
specific to individual risk of local regional recurrences. Instead, for personalised 
follow-up it is required to have more precise estimates of local regional 
recurrence probability as a function of time. The objective of this study is to 
identify prognostic factors, and to quantify individualized and time dependent 
local regional recurrence risk rates. METHODS: Prognostic factors for local 
regional recurrence of breast cancer were identified due to a three-step funnel 
approach, including: scoping literature review, expert consultation and stepwise 
multivariate regression analysis. Quantification of the prognostic value of each 
risk factor was performed with a regression model based on a five-year dataset 
of women diagnosed with breast cancer in the Netherlands in 2005 or 2006 
(n=17762). Six-month interval risk probabilities were derived from regression 
estimates by calculating coefficients of the prognostic factors. RESULTS: Eight 
prognostic factors were identified, including: age, tumour size, multifocality, 
gradation, adjuvant chemo-, adjuvant radiation-, hormonal therapy and triple 
negative status. Expected inter-patient variability was elucidated by average, and 
high risk example patient types with local regional, non-uniform distributed, 
recurrence risks of 5.2% and 12% over a five-year period. CONCLUSIONS: It is 
concluded that local regional recurrence risks are not distributed uniformly, and 
time depended, over the five-year follow-up period. The calculated prognostic 
value of the factors enables quantification of risks for local regional recurrences 
on six-month time intervals for the individual patient. Implicating improved 
allocation of hospital capacities and resources, local regional recurrence risk 
profiling is a first step towards tailored follow-up in breast cancer care.  
 
PCN125  
QUANTIFICATION OF BENEFITS AND RISKS IN MEDICAL IMAGING TESTING:  
A LITERATURE REVIEW  
Agapova M1, Devine B1, Bresnahan BW2, Garrison L3 
1University of Washington, Seattle, WA, USA, 2University of Washington, Seattle , WA, USA, 
3University of Washington School of Pharmacy, Seattle, WA, USA  
OBJECTIVES: Appropriate use of medical imaging tests is a growing area of policy 
discussion. Quantitative methods can characterize benefits and risks of medical 
imaging tests and distinguish necessary from unnecessary utilization.  
Our objective was to assess the extent of quantitative benefit-risk analyses (BRA) 
published in medical imaging testing. METHODS: Using PubMed and the 
Cochrane Library, a computerized search was performed to identify studies 
published between January, 1979 and January, 2013. The search was limited  
to include only studies that quantified benefits and risks/harms of ionizing 
radiation imaging in screening or diagnostics. RESULTS: Seventy-eight studies 
called for the need to weigh benefits and risks associated with medical imaging 
tests but only seven studies quantified at least one benefit and one risk/harm. Of 
these, two studies reported BRA of mammography. Three studies addressed 
positron emission tomography (PET): two studies assessed BRA of full body  
PET in cancer screening and one study assessed BRA of PET in lung cancer 
diagnosis. The remaining two studies reported BRA of computed tomography 
colonography. Of the four studies published in English, benefits were reported in 
terms of life extension, and harms were reported as radiation-related cancer risk 
or loss of life-years. Studies used micro-simulation modeling, epidemiological or 
survey methods. CONCLUSIONS: This review illustrates that a gap exists 
between the number of studies referring to the need for assessing the benefit-
risk balance in medical imaging and the number of studies measuring that 
balance. Challenges such as translating imaging information into impacts  
on patient outcomes, multiple applications of imaging tests, difficulty in 
measuring harms from ionizing radiation and additional procedures spurred 
from false positive results hinder the necessary movement toward using 
quantitative methods. Meeting the goals of patient-centered outcomes and 
understanding areas of appropriate use, overutilization and underutilization 
requires further development of a framework for quantitative BRA of medical 
imaging tests.  
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OBJECTIVES: Willingness to pay (WTP) for new health technologies may vary 
between interventions that prolong patients' life-expectancy and interventions 
that only improve patients' quality of life (QoL), and among different types of 
disease. We determined how Israeli oncologists and family physicians value life-
prolongation vs. QoL-enhancing outcomes attributable to cancer and congestive 
heart failure (CHF) interventions. METHODS: We presented physicians with two 
scenarios involving a hypothetical patient with metastatic cancer expected to 
survive 12-months with current treatment. In a life-prolongation scenario, we 
suggested that a new treatment increases survival at an incremental cost of 
$50,000 over the standard of care. Participants were asked what minimum 
improvement in median months of survival the new therapy would need to 
provide for them to recommend it over standard of care. In the QoL-enhancing 
scenario, we asked the maximum WTP for an intervention that leads to the same 
survival as the standard treatment, but increases patient's QoL from 50 to 75 (on 
a 0-100 scale). We replicated these scenarios substituting a patient with CHF 
NYHA Class IV instead of metastatic cancer. We derived the incremental cost-
effectiveness ratio (ICER) per QALY gained threshold implied by each response. 
RESULTS: In the life-prolongation scenario the median cost-effectiveness 
thresholds implied by oncologists were $150,000/QALY and $100,000/QALY for 
cancer and CHF respectively. Median cost-effectiveness thresholds implied by 
family physicians were $50,000/QALY regardless the disease type. WTP for the 
QoL-enhancing scenarios was $60,000/QALY and did not differ by physicians' 
specialty or disease type. CONCLUSIONS: Our findings suggest that family 
physicians value life-prolonging and QoL-enhancing interventions roughly 
equally, while oncologists value interventions that extend survival more highly 
than those that only improve QoL. These findings may have important 
implications for coverage and reimbursement decisions of new technologies.  
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OBJECTIVES: To understand relative price differential for cancer drugs in the U.S. 
and the U.K.. Develop implications for pricing strategy and patient access for 
cancer drugs. METHODS: Ten branded cancer drugs were selected and their 
prices for similar dose and packaging were compared in the U.S. and the U.K. 
Prices were analyzed for the end of 2011 and 2012. Historical exchange rates 
were used to convert British pounds to US dollars. Relative price discount was 
calculated for all selected cancer drugs. KOLs and payers were interviewed to 
understand current and future implications of this price differential. RESULTS: 
The median price discount for selected ten branded cancer drugs in the UK 
versus the United States was ~50%. The range of discount for 10 branded cancer 
drugs was 27%-61%. The price discount for oral small molecule drugs was higher 
than for biologics (55% vs. 45%). Since the U.K. is one of the few remaining free 
pricing markets in Europe, other European markets are likely to have even higher 
discounts relative to the prices in the U.S.. Due to rising coinsurance of specialty 
products, U.S. cancer patients bear significantly higher costs than patients in the 
UK. KOL and payer interviews suggest U.S. pricing trends for cancer drugs are 
unlikely to be sustained at this level in the future. CONCLUSIONS: U.S. cancer 
drug prices are significantly higher than the prices in the U.K. This price 
differential is unlikely to be sustained in the future.  
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